Literature DB >> 23159167

Multiplicity-dependent activation of a serine protease-dependent cytomegalovirus-associated programmed cell death pathway.

A Louise McCormick1, Linda Roback, Grace Wynn, Edward S Mocarski.   

Abstract

At a low MOI (≤0.01), cytomegalovirus-associated programmed cell death terminates productive infection via a pathway triggered by the mitochondrial serine protease HtrA2/Omi. This infected cell death is associated with late phase replication events naturally suppressed by the viral mitochondrial inhibitor of apoptosis (vMIA). Here, higher MOI (ranging from 0.1-3.0) triggers cell death earlier during infection independent of viral DNA synthesis. Thus, MOI-dependent activating signals early, at high MOI, or late, at low MOI, during replication promote serine protease-dependent death that is suppressed by vMIA. Treatment with an antioxidant targeting reactive oxygen species (ROS) or the serine protease inhibitor N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) delays cell death, and the combination has an additive impact. These studies identify serine proteases and ROS as important factors triggering programmed cell death induced by vMIA-deficient virus, and show that this death pathway occurs earlier and reduces viral yields as the MOI is increased.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159167      PMCID: PMC3534952          DOI: 10.1016/j.virol.2012.08.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation.

Authors:  A Skaletskaya; L M Bartle; T Chittenden; A L McCormick; E S Mocarski; V S Goldmacher
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  DNA of human cytomegalovirus: size heterogeneity and defectiveness resulting from serial undiluted passage.

Authors:  M F Stinski; E S Mocarski; D R Thomsen
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

3.  Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs.

Authors:  H Zhu; J P Cong; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

4.  DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA.

Authors:  Jason W Upton; William J Kaiser; Edward S Mocarski
Journal:  Cell Host Microbe       Date:  2012-03-15       Impact factor: 21.023

5.  Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis.

Authors:  A Louise McCormick; Christopher D Meiering; Geoffrey B Smith; Edward S Mocarski
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter.

Authors:  Soo Jung Kim; Thomas K Varghese; Zheng Zhang; Lee C Zhao; Gail Thomas; Mary Hummel; Michael Abecassis
Journal:  Am J Transplant       Date:  2005-07       Impact factor: 8.086

7.  Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication.

Authors:  Mercedes Reboredo; Richard F Greaves; Gabriele Hahn
Journal:  J Gen Virol       Date:  2004-12       Impact factor: 3.891

8.  Role of murine cytomegalovirus US22 gene family members in replication in macrophages.

Authors:  Carine Ménard; Markus Wagner; Zsolt Ruzsics; Karina Holak; Wolfram Brune; Ann E Campbell; Ulrich H Koszinowski
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Cytomegalovirus gene regulation by reactive oxygen species. Agents in atherosclerosis.

Authors:  E Speir
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

10.  Functional profiling of a human cytomegalovirus genome.

Authors:  Walter Dunn; Cassie Chou; Hong Li; Rong Hai; David Patterson; Viktor Stolc; Hua Zhu; Fenyong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

View more
  7 in total

1.  Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

2.  Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

3.  Suppression of RIP3-dependent necroptosis by human cytomegalovirus.

Authors:  Shinya Omoto; Hongyan Guo; Ganesh R Talekar; Linda Roback; William J Kaiser; Edward S Mocarski
Journal:  J Biol Chem       Date:  2015-03-16       Impact factor: 5.157

Review 4.  Viral modulation of programmed necrosis.

Authors:  William J Kaiser; Jason W Upton; Edward S Mocarski
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

5.  THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.

Authors:  Qingxue Li; Adrian R Wilkie; Melodie Weller; Xueqiao Liu; Jeffrey I Cohen
Journal:  PLoS Pathog       Date:  2015-07-06       Impact factor: 6.823

6.  Interplay of autophagy and apoptosis during murine cytomegalovirus infection of RPE cells.

Authors:  Juan Mo; Ming Zhang; Brendan Marshall; Sylvia Smith; Jason Covar; Sally Atherton
Journal:  Mol Vis       Date:  2014-08-14       Impact factor: 2.367

7.  Multiple Autonomous Cell Death Suppression Strategies Ensure Cytomegalovirus Fitness.

Authors:  Pratyusha Mandal; Lynsey N Nagrani; Liliana Hernandez; Anita Louise McCormick; Christopher P Dillon; Heather S Koehler; Linda Roback; Emad S Alnemri; Douglas R Green; Edward S Mocarski
Journal:  Viruses       Date:  2021-08-27       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.